SEC11A Antibody

What is SEC11A and what is its primary cellular function?

SEC11A (Signal peptidase complex catalytic subunit SEC11A), also known as SEC11L1, SPC18, or SPCS4A, belongs to the peptidase S26B family. It functions as a critical component of the microsomal signal peptidase complex, which cleaves signal peptides from nascent proteins during their translocation into the endoplasmic reticulum lumen. This process is essential for proper protein trafficking and secretion in eukaryotic cells. The protein has a calculated molecular weight of 21 kDa but is commonly observed at 17-21 kDa in experimental contexts, possibly due to post-translational modifications or alternative splicing .

What types of SEC11A antibodies are available for research purposes?

SEC11A antibodies are available in multiple formats to accommodate different research needs. The two main types are:

• Polyclonal antibodies: Such as rabbit polyclonal antibodies (e.g., 14753-1-AP), which recognize multiple epitopes on the SEC11A protein, potentially providing stronger signals in various applications .

• Monoclonal antibodies: Including mouse monoclonal antibodies (e.g., 67379-1-Ig), which target specific epitopes and may provide more consistent results across experiments .

Both antibody types have been validated for Western blot, immunohistochemistry, and ELISA applications, with demonstrated reactivity against human, mouse, and rat samples .

How should researchers choose between polyclonal and monoclonal SEC11A antibodies?

The selection between polyclonal and monoclonal SEC11A antibodies should be based on the specific research objectives:

• Choose polyclonal antibodies when:

  • Detecting low abundance proteins is necessary, as they often provide higher sensitivity

  • The native protein conformation needs to be detected

  • Your research involves preliminary investigations where protein expression patterns are still being established

• Choose monoclonal antibodies when:

  • Consistent results across multiple experiments are crucial

  • Specific epitopes need to be detected

  • Background signal must be minimized

  • Quantitative comparisons between samples are required

Additionally, consider the experimental technique and sample type when selecting an antibody. For example, rabbit polyclonal SEC11A antibodies have been specifically validated in mouse testis and human colon tissues, while mouse monoclonal antibodies have shown reliable results in multiple cell lines including HeLa, HSC-T6, HepG2, and others .

What are the optimal dilution ratios for SEC11A antibodies in different applications?

The appropriate dilution ratios for SEC11A antibodies vary by application and specific antibody used:

Researchers should note that these are recommended starting points, and optimization for specific experimental conditions may be necessary. The higher dilution range for monoclonal antibodies reflects their typically greater specificity and reduced background compared to polyclonal antibodies .

What sample types have been validated for SEC11A antibody detection?

SEC11A antibodies have been validated across multiple sample types, showing reliable detection in:

For Western blot applications:

• Cell lines: HeLa, HSC-T6, HepG2, Jurkat, K-562, NIH/3T3, and 4T1 cells

• Tissue samples: Mouse testis tissue, human colon tissue

For immunohistochemistry applications:

• Human colon cancer tissue

• Human liver cancer tissue

The antibodies show cross-reactivity with human, mouse, and rat SEC11A, making them versatile for comparative studies across species .

What are the recommended antigen retrieval methods for SEC11A immunohistochemistry?

For optimal SEC11A detection in immunohistochemistry applications, the following antigen retrieval methods are recommended:

• Primary method: TE buffer pH 9.0

• Alternative method: Citrate buffer pH 6.0

The selection between these methods may depend on tissue type and fixation procedures. Proper antigen retrieval is particularly important for formalin-fixed, paraffin-embedded (FFPE) tissues, where epitope masking can reduce antibody binding efficiency .

How is SEC11A expression associated with cancer progression and prognosis?

Research has established significant associations between SEC11A upregulation and cancer outcomes:

In head and neck squamous cell carcinoma, high SEC11A expression is independently associated with:

• Shorter progression-free survival (PFS) (HR: 2.075, 95%CI: 1.447–2.977, p<0.001)

• Poorer disease-specific survival (DSS) (HR: 2.023, 95%CI: 1.284–3.187, p=0.002)

This prognostic value has been confirmed in multiple subtypes, including laryngeal squamous cell carcinoma, oral cavity-related squamous cell carcinoma, and oropharynx-related squamous cell carcinoma .

Additionally, SEC11A upregulation has been linked to worse outcomes in:

• Gastric cancer

• Colorectal cancer

• Basal-like bladder cancer

• Esophageal squamous cell carcinoma

Researchers investigating cancer progression should consider SEC11A as a potential biomarker for prognosis and disease stratification .

What techniques should be employed to investigate the relationship between SEC11A copy number alterations and expression levels?

To study the relationship between SEC11A gene amplification and expression:

• Measure gene copy number using:

  • Comparative genomic hybridization (CGH)

  • Fluorescence in situ hybridization (FISH)

  • Next-generation sequencing (NGS) approaches

• Quantify mRNA expression through:

  • Quantitative RT-PCR

  • RNA-seq analysis

• Assess protein expression via:

  • Western blot using validated SEC11A antibodies

  • Immunohistochemistry on tissue sections

• Perform correlation analysis:

  • Calculate Pearson's correlation coefficient between copy number and expression data

  • Previous studies have identified a moderate positive correlation (Pearson's r = 0.53, p<0.001) between SEC11A copy number and expression levels in head and neck squamous cell carcinoma

• Validate in multiple tumor types:

  • Compare relationships across different cancer types to establish consistency of findings

This multi-modal approach provides robust evidence for gene dosage effects on protein expression and potential functional consequences in disease contexts.

How can researchers investigate the relationship between SEC11A expression and immune cell infiltration in the tumor microenvironment?

To explore SEC11A's relationship with the tumor immune microenvironment:

• Employ computational deconvolution methods:

  • Utilize tools like TIMER 2.0 (http://timer.cistrome.org/) to estimate immune cell proportions from bulk RNA-seq data

  • Quantify correlations between SEC11A expression and specific immune cell populations

• Validate computational findings with immunohistochemistry:

  • Use multiplexed IHC to simultaneously detect SEC11A and immune cell markers

  • Quantify spatial relationships between SEC11A-expressing cells and immune populations

• Assess functional relationships through:

  • Gene set enrichment analysis (GSEA) to identify pathways associated with high/low SEC11A expression

  • Co-culture experiments with immune and tumor cells to establish direct effects

• Interpret immune correlation patterns:

  • SEC11A expression has been shown to negatively correlate with CD8+ T cells and B cells

  • Positive correlations observed with cancer-associated fibroblasts and myeloid-derived suppressor cells (MDSCs)

  • These patterns suggest SEC11A may contribute to an immunosuppressive microenvironment

Understanding these relationships can inform combination therapies targeting both SEC11A and immune checkpoints in cancer treatment.

How should researchers address multiple molecular weight bands when detecting SEC11A by Western blot?

When multiple bands appear in SEC11A Western blots:

• Verify expected molecular weight range: SEC11A has a calculated molecular weight of 21 kDa but is commonly observed between 17-21 kDa on Western blots .

• Investigate potential causes:

  • Post-translational modifications: Phosphorylation, glycosylation, or other modifications may alter migration patterns

  • Alternative splicing: SEC11A has multiple isoforms that may be detected simultaneously

  • Degradation products: Improper sample handling may result in protein fragmentation

  • Cross-reactivity: Particularly with polyclonal antibodies, which may detect related proteins

• Validation approaches:

  • siRNA/shRNA knockdown: Confirm which bands disappear when SEC11A is depleted

  • Blocking peptide: Compete antibody binding with the original immunogen

  • Multiple antibodies: Test different antibodies targeting distinct epitopes

  • Mass spectrometry: Identify protein composition of suspicious bands

• Optimization strategies:

  • Adjust sample preparation conditions to preserve protein integrity

  • Optimize gel percentage for better resolution in the 15-25 kDa range

  • Test different blocking agents to reduce non-specific binding

Each band should be documented and carefully interpreted in the context of the experimental system and expected SEC11A behavior.

What controls should be included when validating SEC11A antibodies for new experimental systems?

A comprehensive validation strategy for SEC11A antibodies should include:

Positive controls:

• Cell lines with confirmed SEC11A expression (e.g., HeLa, HSC-T6, HepG2)

• Tissue samples with validated expression (e.g., mouse testis, human colon)

• Recombinant SEC11A protein (when available)

Negative controls:

• SEC11A knockout or knockdown samples (CRISPR-Cas9 or siRNA)

• Pre-immune serum (for polyclonal antibodies)

• Isotype control (for monoclonal antibodies)

• Primary antibody omission

• Blocking peptide competition

Specificity controls:

• Detection of endogenous vs. overexpressed protein

• Cross-validation with multiple antibodies targeting different epitopes

• Mass spectrometry confirmation of immunoprecipitated protein

Application-specific controls:

• For IHC: Appropriate antigen retrieval controls and tissue-specific controls

• For Western blot: Loading controls and molecular weight markers

• For immunoprecipitation: Non-specific IgG controls

Thorough validation ensures reliable interpretation of results and enhances reproducibility across research groups .

How can contradictory results between SEC11A protein and mRNA expression levels be reconciled?

When SEC11A protein and mRNA expression levels show discrepancies:

• Consider post-transcriptional regulation mechanisms:

  • microRNA targeting SEC11A transcripts may affect translation efficiency

  • RNA-binding proteins might alter mRNA stability or translation

  • Alternative splicing could generate protein isoforms not detected by certain antibodies

• Evaluate protein stability factors:

  • Ubiquitin-proteasome pathway activity may vary between samples

  • Autophagy rates could impact protein turnover

  • Secretion or relocalization of the protein may affect detection in certain compartments

• Assess technical considerations:

  • Different sensitivities between protein and mRNA detection methods

  • Antibody recognition may be affected by post-translational modifications

  • Sample preparation differences between protein and RNA extraction

• Experimental approaches to resolve discrepancies:

  • Measure protein half-life using cycloheximide chase experiments

  • Assess proteasome contribution using inhibitors like MG132

  • Investigate translation efficiency using polysome profiling

  • Validate with multiple antibodies targeting different epitopes

  • Perform absolute quantification of both mRNA and protein when possible

• Integrate with biological context:

  • Consider cell type-specific regulation mechanisms

  • Evaluate stress conditions that might uncouple transcription and translation

  • Examine cell cycle dependence of expression patterns

These investigations can provide insights into the complex regulatory mechanisms governing SEC11A expression and function in different contexts.

How might SEC11A function be connected to therapeutic resistance mechanisms in cancer?

The potential role of SEC11A in therapy resistance warrants investigation through:

• Correlation studies:

  • Analyze SEC11A expression in pre- and post-treatment tumor samples

  • Compare expression in responsive versus resistant tumors

  • Evaluate associations with known resistance biomarkers

• Mechanistic investigations:

  • Examine SEC11A's impact on drug efflux pumps through its role in protein processing

  • Investigate connections to the unfolded protein response and ER stress pathways

  • Assess relationships with growth factor receptor trafficking and signaling

• Experimental approaches:

  • Generate SEC11A knockdown/overexpression models in resistant cell lines

  • Perform drug sensitivity testing with SEC11A modulation

  • Combine SEC11A targeting with standard therapeutic agents

  • Use proteomics to identify SEC11A-processed proteins involved in resistance

The established connections between SEC11A and EGFR/ERK/Akt signaling pathways suggest potential involvement in resistance to targeted therapies, warranting dedicated investigation in treatment-refractory disease models .

What methodological approaches can distinguish between SEC11A's direct catalytic effects and its potential scaffolding functions?

To differentiate between catalytic and non-catalytic SEC11A functions:

• Structure-function studies:

  • Generate catalytically inactive mutants through site-directed mutagenesis of active site residues

  • Create domain deletion constructs to isolate scaffolding regions

  • Perform complementation assays with mutant variants in SEC11A-depleted cells

• Proteomic approaches:

  • Conduct BioID or proximity labeling to identify interacting partners

  • Compare interactomes of wild-type versus catalytically inactive SEC11A

  • Use quantitative proteomics to identify substrates by comparing secretomes with and without SEC11A

• Advanced imaging techniques:

  • Implement live-cell FRET sensors to monitor protein-protein interactions

  • Utilize super-resolution microscopy to visualize SEC11A localization relative to substrates and partners

  • Track protein trafficking in the presence of different SEC11A variants

• Biochemical assays:

  • Develop in vitro signal peptidase assays with recombinant SEC11A

  • Test activity of various mutants and their ability to rescue phenotypes

  • Investigate association with other signal peptidase complex components

These approaches can comprehensively map the dual functions of SEC11A and their relative contributions to cellular phenotypes in normal and disease states.